These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

865 related items for PubMed ID: 12183849

  • 1. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
    [Abstract] [Full Text] [Related]

  • 2. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [Abstract] [Full Text] [Related]

  • 3. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH, Alfayoumi F.
    Prog Cardiovasc Dis; 2006 Jan; 48(5):326-41. PubMed ID: 16627048
    [Abstract] [Full Text] [Related]

  • 4. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B.
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [Abstract] [Full Text] [Related]

  • 5. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM, Schmieder RE.
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [Abstract] [Full Text] [Related]

  • 6. Regression of left ventricular hypertrophy: do antihypertensive classes differ?
    Sheridan DJ.
    J Hypertens Suppl; 2000 Jul; 18(3):S21-7. PubMed ID: 10952084
    [Abstract] [Full Text] [Related]

  • 7. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up.
    Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E.
    J Hypertens Suppl; 1996 Dec; 14(5):S43-9. PubMed ID: 9120684
    [Abstract] [Full Text] [Related]

  • 8. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.
    Messerli FH, Ketelhut R.
    J Cardiovasc Pharmacol; 1993 Dec; 22 Suppl 1():S7-13. PubMed ID: 7507540
    [Abstract] [Full Text] [Related]

  • 9. [Cardiac failure in hypertensive cardiopathy].
    Verdecchia P.
    Ital Heart J; 2000 Jun; 1 Suppl 2():72-7. PubMed ID: 10905132
    [Abstract] [Full Text] [Related]

  • 10. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H, Li LM, Cao WH, Sun NL, Liu MZ, Hu YH.
    Ann Hum Biol; 2005 Jun; 32(1):30-43. PubMed ID: 15788353
    [Abstract] [Full Text] [Related]

  • 11. Antihypertensive drugs and the heart.
    Diamond JA, Phillips RA.
    Minerva Med; 2005 Aug; 96(4):247-60. PubMed ID: 16179892
    [Abstract] [Full Text] [Related]

  • 12. [Sex differences in the correlation between obesity and hypertension with left ventricular mass and hypertrophy].
    Kuch B, Muscholl M, Luchner A, Döring A, Riegger GA, Schunkert H, Hense HW.
    Z Kardiol; 1996 May; 85(5):334-42. PubMed ID: 8711946
    [Abstract] [Full Text] [Related]

  • 13. Left ventricular hypertrophy: a potent cardiovascular risk factor and its relationship to office and ambulatory blood pressure.
    Mansoor GA, Massie BM.
    Blood Press Monit; 1999 May; 4 Suppl 1():S19-22. PubMed ID: 10822413
    [Abstract] [Full Text] [Related]

  • 14. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
    Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG, CHARM Investigators and Committees.
    Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
    [Abstract] [Full Text] [Related]

  • 15. Heart failure and its treatment in women. Role of hypertension, diabetes, and estrogen.
    Regitz-Zagrosek V, Lehmkuhl E.
    Herz; 2005 Aug; 30(5):356-67. PubMed ID: 16132238
    [Abstract] [Full Text] [Related]

  • 16. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients.
    Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C.
    Ital Heart J; 2004 Jul; 5(7):505-10. PubMed ID: 15487267
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H.
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [Abstract] [Full Text] [Related]

  • 18. [Hypertension as a function of age].
    Gensini GF, Corradi F.
    Ital Heart J; 2000 Jun; 1 Suppl 2():23-31. PubMed ID: 10905125
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B.
    Blood Press Suppl; 1994 Jun; 2():35-40. PubMed ID: 8061844
    [Abstract] [Full Text] [Related]

  • 20. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.
    Nefrologia; 2008 Jun; 28 Suppl 3():39-48. PubMed ID: 19018737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.